Department of Internal Medicine and Clinical Epidemiology, Princess Alexandra Hospital, Brisbane, QLD.
Med J Aust. 2011 Jul 4;195(1):29-33. doi: 10.5694/j.1326-5377.2011.tb03184.x.
A recently published critique of a set of Australian clinical practice guidelines (CPG) highlighted problematic issues in guideline development concerning conflicts of interest of guideline panellists, validity and strength of recommendations, and involvement of end users and external stakeholders. Management of financial or intellectual conflicts of interest requires: full disclosure; limitations on industry or agency financial support during guideline development; a representative panel that includes conflict-free members; and only conflict-free panellists to be involved in drafting guideline recommendations. Guideline panels should consider adopting the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system to assist in determining the validity and strength of recommendations. Guideline panels should seek formal feedback from external stakeholders and end users. Enacting such policies aims to lend greater transparency and credibility to CPG, limit protracted and unhelpful interpretive debates, and promote wider use of CPG.
最近发表的一篇对澳大利亚临床实践指南(CPG)的评论,强调了指南制定过程中存在的问题,包括指南小组成员的利益冲突、建议的有效性和力度,以及终端用户和外部利益相关者的参与。管理财务或知识利益冲突需要:充分披露;限制指南制定过程中的行业或机构财政支持;包括无冲突成员的代表性小组;并且只有无冲突的小组成员才能参与起草指南建议。指南小组应考虑采用 GRADE(推荐评估、制定和评估分级)系统,以协助确定建议的有效性和力度。指南小组应寻求外部利益相关者和终端用户的正式反馈。制定这些政策旨在使 CPG 更加透明和可信,限制冗长无益的解释性辩论,并促进更广泛地使用 CPG。